Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Enrolling by invitation 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 44INDUSTRY 17NIH 3OTHER_GOV 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3Breast 3Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasms 79Lymphoma 62Breast Neoplasms 61Prostatic Neoplasms 60Multiple Myeloma 60Lung Neoplasms 55Neoplasm Metastasis 54Ovarian Neoplasms 47Leukemia, Myeloid, Acute 47Colorectal Neoplasms 41Hematologic Neoplasms 40Melanoma 39Carcinoma, Non-Small-Cell Lung 38Pancreatic Neoplasms 31Lymphoma, Non-Hodgkin 31Glioma 31Brain Neoplasms 30Urinary Bladder Neoplasms 28Myelodysplastic Syndromes 28Sarcoma 26Carcinoma, Renal Cell 26Glioblastoma 25Fallopian Tube Neoplasms 25Neuroblastoma 23Triple Negative Breast Neoplasms 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 21Stomach Neoplasms 19Small Cell Lung Carcinoma 19Squamous Cell Carcinoma of Head and Neck 18

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Uterine Neoplasms × 1 year × Clear all
NCT03762733 2026-06-05

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
500 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡